NCT03969680

Mesenchymal Stem Cell Transplantation for Osteoarthritis

Autologous Mesenchymal Stem Cell Transplantation for the Treatment of Knee Osteoarthritis

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Yantai Yuhuangding Hospital · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BMSCs) plus autologous platelet rich plasma (PRP) in the treatment of severe knee osteoarthritis.

Detailed description

This is a single centered, randomized, single blind phase II clinical study. Patients will be divided into two groups of case and control. Patients of case group will receive intra-articular injection of autologous BMSCs suspended in 3 ml autologous PRP for 3 times, patients of control group will receive intra-articular injection of 3 ml of autologous PRP for 3 times. The investigators designed this clinical study to evaluate therapeutic effects of BM-MSCs in patients with severe knee osteoarthritis.

Conditions

• Knee Osteoarthritis

Interventions

Type	Name	Description
BIOLOGICAL	Auotologous BMSCs plus autologous PRP	30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP.
BIOLOGICAL	Auotologous PRP	30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.

Timeline

• Start date: 2019-07-08
• Primary completion: 2023-10-30
• Completion: 2023-12-28
• First posted: 2019-05-31
• Last updated: 2024-01-24

Locations

1 site across 1 country: China